Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2757-2760

  Terao, Shuji ^a,b   Shirakawa, Toshiro ^a,c   Goda, Kazumasa ^b   Kamidono, Sadao ^b   Fujisawa, Masato ^b   Gotoh, Akinobu ^a,c,d  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d NONE   (Japan)

Author keywords

Adenovirus; Bladder cancer; Gene therapy; Recombinant IL 2

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; RECOMBINANT ENZYME; RECOMBINANT INTERLEUKIN 2; THYMIDINE KINASE; VIRUS ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROUS SARCOMA ONCOVIRUS; TUMOR GROWTH; VIRAL GENE THERAPY;

ACYCLOVIR; ADENOVIRIDAE; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-2; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 22944441622     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Edelman MJ: New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep 2: 379-385, 2000.
2. Block T: Chemotherapy of bladder carcinoma. Current status and trends. Urology A 33: 557-567, 1994.
3. Witjes JA, Wullink M, Oosterhof GO and de Mulder P: Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 31: 414-419, 1997.
4. Freund CT, Sutton MA, Dang T, Contant CF, Rowley D and Lerner SP: Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res 20: 1359-1365, 2000.
5. Sutton MA, Berkman SA, Chen SH, Block A, Dang TD, Kattan MW, Wheeler TM, Rowley DR, Woo SL and Lerner SP: Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology 49: 173-180, 1997.
6. Connor J, Bannerji R, Saito S, Heston W, Fair W and Gilboa E: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1134, 1993.
7. Graham FL and Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol 3: 207-220, 1995.
8. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC and Chung LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761, 1991.
9. Vile RG, Tuszynski A and Castleden S: Retroviral vectors. From laboratory tools to molecular medicine. Mol Biotechnol 5: 139-158, 1996.
10. Deonarain MP, Spooner RA and Epenetos AA: Genetic delivery of enzymes for cancer therapy. Gene Ther 2: 235-244, 1995.
11. Ramesh R, Marrogi AJ, Munshi A, Abboud CN and Freeman SM: In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol 24: 829-838, 1996.
12. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C and Chong H: Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71: 267-274, 1997.
13. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM and Batshaw ML: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158, 2003.